Opthea Ltd Asset Resilience Ratio
Opthea Ltd asset resilience ratio. Opthea Ltd (OPT) has an Asset Resilience Ratio of 60.86% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OPT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Opthea Ltd (1989–2025)
Asset resilience ratio of Opthea Ltd from 1989 to 2025. This chart shows how Opthea Ltd's Asset Resilience Ratio has changed over time. Read OPT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Opthea Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Opthea Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$34.41 Million | 60.86% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$34.41 Million | 60.86% |
Asset Resilience Insights
- Very High Liquidity: Opthea Ltd maintains exceptional liquid asset reserves at 60.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Opthea Ltd Industry Peers by Asset Resilience Ratio
Compare Opthea Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Opthea Ltd Asset Resilience Ratio by Year (1989–2025)
Opthea Ltd asset resilience ratio by year from 1989 to 2025. The table below shows the annual Asset Resilience Ratio data for Opthea Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 60.59% | AU$34.41 Million ≈ $24.35 Million |
AU$56.80 Million ≈ $40.19 Million |
+17.82pp |
| 2024-06-30 | 42.77% | AU$80.74 Million ≈ $57.13 Million |
AU$188.79 Million ≈ $133.58 Million |
-9.27pp |
| 2023-06-30 | 52.04% | AU$77.12 Million ≈ $54.57 Million |
AU$148.19 Million ≈ $104.85 Million |
+14.51pp |
| 2022-06-30 | 37.54% | AU$32.78 Million ≈ $23.19 Million |
AU$87.32 Million ≈ $61.79 Million |
-18.14pp |
| 2021-06-30 | 55.68% | AU$102.65 Million ≈ $72.63 Million |
AU$184.36 Million ≈ $130.45 Million |
-0.76pp |
| 2020-06-30 | 56.44% | AU$40.57 Million ≈ $28.71 Million |
AU$71.89 Million ≈ $50.86 Million |
+18.87pp |
| 2019-06-30 | 37.58% | AU$14.15 Million ≈ $10.01 Million |
AU$37.66 Million ≈ $26.65 Million |
-6.62pp |
| 2018-06-30 | 44.20% | AU$20.36 Million ≈ $14.41 Million |
AU$46.08 Million ≈ $32.60 Million |
-19.24pp |
| 2017-06-30 | 63.43% | AU$35.87 Million ≈ $25.38 Million |
AU$56.54 Million ≈ $40.01 Million |
+62.69pp |
| 2016-06-30 | 0.74% | AU$126.28K ≈ $89.35K |
AU$17.05 Million ≈ $12.07 Million |
+0.72pp |
| 2007-06-30 | 0.02% | AU$12.05K ≈ $8.53K |
AU$56.71 Million ≈ $40.12 Million |
-22.58pp |
| 2006-06-30 | 22.60% | AU$9.90 Million ≈ $7.00 Million |
AU$43.79 Million ≈ $30.98 Million |
+22.56pp |
| 2005-06-30 | 0.04% | AU$14.27K ≈ $10.10K |
AU$32.92 Million ≈ $23.29 Million |
-0.05pp |
| 2004-06-30 | 0.09% | AU$27.63K ≈ $19.55K |
AU$29.46 Million ≈ $20.85 Million |
-0.09pp |
| 2003-06-30 | 0.19% | AU$46.72K ≈ $33.05K |
AU$24.83 Million ≈ $17.57 Million |
-0.12pp |
| 2002-06-30 | 0.31% | AU$72.06K ≈ $50.99K |
AU$23.49 Million ≈ $16.62 Million |
-0.11pp |
| 2001-06-30 | 0.42% | AU$102.57K ≈ $72.57K |
AU$24.37 Million ≈ $17.24 Million |
-53.72pp |
| 2000-06-30 | 54.14% | AU$8.24 Million ≈ $5.83 Million |
AU$15.22 Million ≈ $10.77 Million |
+11.84pp |
| 1998-06-30 | 42.31% | AU$1.90 Million ≈ $1.34 Million |
AU$4.49 Million ≈ $3.18 Million |
+51.52pp |
| 1997-06-30 | -9.22% | AU$-506.07K ≈ $-358.08K |
AU$5.49 Million ≈ $3.89 Million |
-14.28pp |
| 1993-06-30 | 5.06% | AU$82.83K ≈ $58.61K |
AU$1.64 Million ≈ $1.16 Million |
-4.16pp |
| 1992-06-30 | 9.22% | AU$153.88K ≈ $108.88K |
AU$1.67 Million ≈ $1.18 Million |
+3.88pp |
| 1991-06-30 | 5.34% | AU$70.55K ≈ $49.92K |
AU$1.32 Million ≈ $935.50K |
+2.18pp |
| 1990-06-30 | 3.16% | AU$48.38K ≈ $34.24K |
AU$1.53 Million ≈ $1.08 Million |
-13.20pp |
| 1989-06-30 | 16.36% | AU$400.15K ≈ $283.13K |
AU$2.45 Million ≈ $1.73 Million |
-- |
About Opthea Ltd
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more